MX350126B - Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo. - Google Patents

Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo.

Info

Publication number
MX350126B
MX350126B MX2014002595A MX2014002595A MX350126B MX 350126 B MX350126 B MX 350126B MX 2014002595 A MX2014002595 A MX 2014002595A MX 2014002595 A MX2014002595 A MX 2014002595A MX 350126 B MX350126 B MX 350126B
Authority
MX
Mexico
Prior art keywords
toxin
difficile
tab
proteins
isolated polypeptide
Prior art date
Application number
MX2014002595A
Other languages
English (en)
Other versions
MX2014002595A (es
Inventor
Larry Ellingsworth
Steven Fuhrmann
Stahl Stefanie Kluepfel
Gregory Glenn
Kerstin Westritschnig
David Flyer
jing hui Tian
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44799993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX350126(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of MX2014002595A publication Critical patent/MX2014002595A/es
Publication of MX350126B publication Critical patent/MX350126B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a polipéptidos aislados C-TAB.G5 y C-TAB.G5.1 que comprenden los dominios de unión al receptor de la toxina A y la toxina B de C. difficile, tal como se define en las secuencias de aminoácido de la SEQ ID NO: 2 y la SEQ ID NO: 4; los polipéptidos aislados C-TAB.G5 y C-TAB.G5.1 se pueden usar para neutralizar los efectos tóxicos de la toxina A y/o la toxina B de C. difficile.
MX2014002595A 2010-09-03 2011-09-05 Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo. MX350126B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37989210P 2010-09-03 2010-09-03
PCT/EP2011/065304 WO2012028741A1 (en) 2010-09-03 2011-09-05 Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof

Publications (2)

Publication Number Publication Date
MX2014002595A MX2014002595A (es) 2014-10-13
MX350126B true MX350126B (es) 2017-08-28

Family

ID=44799993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002595A MX350126B (es) 2010-09-03 2011-09-05 Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo.

Country Status (22)

Country Link
US (6) US9598472B2 (es)
EP (3) EP3895728A1 (es)
JP (1) JP6121421B2 (es)
KR (1) KR101907434B1 (es)
CN (1) CN103957931B (es)
AU (1) AU2011298306B2 (es)
BR (1) BR112014004896B1 (es)
CA (1) CA2873272C (es)
CY (1) CY1118664T1 (es)
DK (1) DK2753352T4 (es)
ES (2) ES2867375T3 (es)
HK (1) HK1200357A1 (es)
HR (1) HRP20170193T4 (es)
HU (1) HUE033342T2 (es)
LT (1) LT2753352T (es)
MX (1) MX350126B (es)
PL (1) PL2753352T5 (es)
PT (1) PT2753352T (es)
RS (1) RS55707B2 (es)
SI (1) SI2753352T2 (es)
WO (1) WO2012028741A1 (es)
ZA (1) ZA201400610B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103957931B (zh) 2010-09-03 2017-10-24 瓦尔内瓦奥地利有限责任公司 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
RU2754446C2 (ru) 2011-04-22 2021-09-02 ВАЙЕТ ЭлЭлСи Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения
AU2016203241B2 (en) * 2011-05-27 2018-05-10 Glaxosmithkline Biologicals S.A. Immunogenic composition
HUE030823T2 (en) 2011-05-27 2017-06-28 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2013084071A2 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
JP6290918B2 (ja) * 2012-12-05 2018-03-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
GB2525177A (en) * 2014-04-14 2015-10-21 New Royal Holloway & Bedford Vaccine
EP3271375B1 (en) * 2015-02-19 2021-02-24 Immune Biosolutions Inc. Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
CN109311950A (zh) * 2016-03-21 2019-02-05 儿童医学中心公司 用于抑制wnt信号传导的组合物和方法
EP3810163A1 (en) 2018-06-19 2021-04-28 GlaxoSmithKline Biologicals SA Immunogenic composition
US20220144924A1 (en) * 2019-02-25 2022-05-12 Previpharma Consulting Gmbh Epitopes of clostridium difficile toxins a and b and uses thereof
WO2021205022A1 (en) 2020-04-09 2021-10-14 Valneva Austria Gmbh Improved methods of producing a lipidated protein
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5736139A (en) 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5547871A (en) 1993-01-25 1996-08-20 American Cyanamid Company Heterologous signal sequences for secretion of insect controlling proteins
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
CN1176658A (zh) * 1994-10-24 1998-03-18 蛇药制品有限公司 治疗和预防艰难梭菌疾病的疫苗和抗毒素
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
WO1997002836A1 (en) 1995-07-07 1997-01-30 Oravax, Inc. Clostridium difficile toxins as mucosal adjuvants
US6365573B1 (en) 1996-10-04 2002-04-02 Neuronz Ltd. Regulation of neural enzymes
DE69737836T2 (de) 1996-12-31 2008-03-06 Altea Therapeutics Corp. Mikroporation von Gewebe zur Verabreichung von bioaktiven Substanzen
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
WO2000061762A1 (en) * 1999-04-09 2000-10-19 Techlab, Inc. RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE)
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US8568742B2 (en) 2000-06-08 2013-10-29 Valneva Austria Gmbh Methods and compositions involving immunostimulatory oligodeoxynucleotides
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
CA2418854A1 (en) 2000-08-17 2002-02-21 Jorg Fritz A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US7858588B2 (en) 2001-05-21 2010-12-28 Intercell Ag Immunostimulatory oligodeoxynucleic molecules
AU2002358616A1 (en) 2001-12-07 2003-06-17 Intercell Ag Immunostimulatory oligodeoxynucleotides
DK1766093T3 (da) * 2004-02-06 2011-10-03 Univ Massachusetts Antistoffer mod clostridium difficile-toksiner og anvendelse deraf
WO2006024024A2 (en) 2004-08-23 2006-03-02 Teva Pharmaceutical Industries Ltd. Solid and crystalline ibandronate sodium and processes for preparation thereof
CN101500581B (zh) * 2006-06-08 2013-10-30 科内尔研究基金会 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
WO2008152429A1 (en) * 2007-06-14 2008-12-18 Health Protection Agency Chemically modified peptides with improved immunogenicity
HUE037932T2 (hu) 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
EP2318515A4 (en) * 2008-08-06 2012-11-14 Emergent Product Dev Uk Ltd DIFFICULT CLOSTRIDIUM VACCINES, AND METHODS OF USE
WO2011060431A2 (en) 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
JP5965389B2 (ja) 2010-04-15 2016-08-03 プロゲニクス ファーマシューティカルズ インコーポレーテッドＰｒｏｇｅｎｉｃｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体
CN103957931B (zh) 2010-09-03 2017-10-24 瓦尔内瓦奥地利有限责任公司 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
RU2754446C2 (ru) * 2011-04-22 2021-09-02 ВАЙЕТ ЭлЭлСи Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения
HUE030823T2 (en) 2011-05-27 2017-06-28 Glaxosmithkline Biologicals Sa Immunogenic composition
GB201206070D0 (en) * 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
JP6290918B2 (ja) * 2012-12-05 2018-03-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
GB201223342D0 (en) 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
US9181632B1 (en) * 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof

Also Published As

Publication number Publication date
ZA201400610B (en) 2015-09-30
HRP20170193T4 (hr) 2022-09-02
ES2631032T3 (es) 2017-08-25
ES2631032T5 (es) 2022-10-26
PT2753352T (pt) 2017-03-08
HUE033342T2 (en) 2017-11-28
CN103957931A (zh) 2014-07-30
PL2753352T3 (pl) 2017-07-31
CA2873272A1 (en) 2012-03-08
EP2753352A1 (en) 2014-07-16
HK1200357A1 (en) 2015-08-07
EP3167899B1 (en) 2021-03-24
CY1118664T1 (el) 2017-07-12
US10821166B2 (en) 2020-11-03
BR112014004896A2 (pt) 2021-01-26
PL2753352T5 (pl) 2022-10-17
DK2753352T5 (da) 2017-05-01
US20170239340A1 (en) 2017-08-24
US20150056238A1 (en) 2015-02-26
RS55707B2 (sr) 2022-10-31
ES2867375T3 (es) 2021-10-20
SI2753352T2 (sl) 2022-10-28
AU2011298306A1 (en) 2014-02-20
HRP20170193T1 (hr) 2017-06-02
AU2011298306B2 (en) 2017-10-19
DK2753352T3 (da) 2017-03-06
EP3167899A1 (en) 2017-05-17
EP2753352B2 (en) 2022-08-10
US20190290747A1 (en) 2019-09-26
CN103957931B (zh) 2017-10-24
EP2753352B1 (en) 2017-01-25
RS55707B1 (sr) 2017-07-31
US20210393761A1 (en) 2021-12-23
US11478540B2 (en) 2022-10-25
CA2873272C (en) 2020-10-27
EP3895728A1 (en) 2021-10-20
MX2014002595A (es) 2014-10-13
US10357557B2 (en) 2019-07-23
US20210121554A1 (en) 2021-04-29
BR112014004896B1 (pt) 2023-02-14
WO2012028741A1 (en) 2012-03-08
US11357844B2 (en) 2022-06-14
KR20140057315A (ko) 2014-05-12
DK2753352T4 (da) 2022-09-12
LT2753352T (lt) 2017-05-25
JP6121421B2 (ja) 2017-04-26
SI2753352T1 (sl) 2017-06-30
US20230173052A1 (en) 2023-06-08
JP2014525249A (ja) 2014-09-29
KR101907434B1 (ko) 2018-10-12
US9598472B2 (en) 2017-03-21

Similar Documents

Publication Publication Date Title
MX350126B (es) Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo.
PH12018501250A1 (en) Chimeric factor viii polypeptides and uses thereof
NZ602634A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
NZ600732A (en) Oxyntomodulin peptide analogue
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
NZ625630A (en) Human il-23 antigen binding proteins
NZ607224A (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
NZ616989A (en) Therapeutic nuclease compositions and methods
NZ600731A (en) Oxyntomodulin peptide analogue
NZ707439A (en) Modified factor ix polypeptides and uses thereof
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
MY182429A (en) Compositions relating to a mutant clostridium difficile toxin and methods thereof
IN2014KN01713A (es)
IN2014KN01714A (es)
IN2014KN01716A (es)
NZ612161A (en) Radiolabled her2 binding peptides
NZ601591A (en) Methods for treating pancreatic cancer
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
WO2012051498A3 (en) Antibodies that bind amyloid oligomers
NZ603196A (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
NZ706884A (en) Fc gamma receptor iib variants
MX2015003310A (es) Moleculas de union il-17a novedosas y usos medicos de las mismas.
NZ600363A (en) Modified porcine somatotropin polypeptides and their uses
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
NZ629309A (en) Tumour necrosis factor receptor fusion proteins and methods of using the same

Legal Events

Date Code Title Description
FG Grant or registration